Skip to main content
Zogenix seeks FDA nod for Dravet syndrome therapy

Zogenix has filed with the FDA a new drug application for Fintepla, or low-dose fenfluramine, oral solution, indicated to treat seizures associated with Dravet syndrome. The submission was backed by results from two late-stage trials and an open-label extension study that showed a median reduction of 66.8% in the frequency of convulsive seizures per month.

Full Story: